CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.83
-0.03 (-2.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.86
Open0.85
Bid0.80 x 2900
Ask1.07 x 1000
Day's Range0.83 - 0.85
52 Week Range0.82 - 2.59
Volume117,553
Avg. Volume110,466
Market Cap27.919M
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT

    Q2 2018 CytRx Corp Earnings Call

  • CytRx Corporation to Present at the 2018 MicroCap Conference
    PR Newswire25 days ago

    CytRx Corporation to Present at the 2018 MicroCap Conference

    LOS ANGELES, Sept. 25, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the 2018 MicroCap Conference on Tuesday, October 2, 2018 at 3:00 P.M. Eastern Daylight Time at the Essex House in New York City. The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. The MicroCap Conference will highlight the most attractive companies across various sectors.

  • CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
    PR Newswirelast month

    CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S

    LOS ANGELES, Sept. 13, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received a milestone payment of $250,000 (USD) from Orphazyme A/S (ORPHA.CO). The payment is a result of Orphazyme dosing the first patient in their Phase 3 clinical trial evaluating arimoclomol in patients with amyotrophic lateral sclerosis (ALS).

  • CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
    PR Newswire2 months ago

    CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018

    LOS ANGELES, Aug. 27, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference. H.C. Wainwright & Co. LLC is an investment bank dedicated to providing corporate finance, strategic advisory, research, sales and trading, and other related services to public and private growth companies across multiple sectors and regions. At the Conference, more than 250 presenting companies and credentialed investors consisting of portfolio managers, hedge fund managers, and family offices will have the opportunity to engage in one-on-one meetings and networking opportunities.

  • ACCESSWIRE2 months ago

    CytRx Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 11:00 AM Eastern Time. ...

  • Associated Press2 months ago

    CytRx: 2Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 10 cents per share. The company's shares closed at $1.15. A year ago, they were trading at $3.78. _____ This story was generated by Automated Insights ...

  • CytRx Corporation Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    CytRx Corporation Reports Second Quarter 2018 Financial Results

    Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), ...

  • PR Newswire3 months ago

    CytRx Corporation Pays Off Balance of Outstanding Debt

    LOS ANGELES, Aug. 1, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has made the final scheduled payment under a long-term loan facility agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P.  As of, August 1, 2018, the Hercules loan was paid in full. "Our current focus is on securing strategic partnerships for our wholly owned subsidiary Centurion BioPharma Corporation.

  • PR Newswire3 months ago

    CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

    LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on Monday, August 6, 2018. CytRx executives Eric L. Curtis, President and Chief Operating Officer, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the financial results as well as provide an overview of corporate achievements of both CytRx Corporation and Centurion BioPharma Corporation. To access the conference call, dial (+1)844-358-6753 (U.S. and Canada) or (+1)216-562-0397 (international callers) and enter the conference ID number: 5991089.  A live and archived webcast will be available in the News and Events/Events Calendar section of the company's website, www.cytrx.com.

  • PR Newswire3 months ago

    CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application

    Breakthrough Personalized Medicine Companion Diagnostic Filed for its Albumin-binding Drug Candidates LOS ANGELES , July 25, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research ...

  • PR Newswire3 months ago

    CytRx Corporation Announces Expiration of Outstanding Warrants

    LOS ANGELES, July 23, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the expiration of warrants for approximately 3.2 million shares of its common stock, effective July 20, 2018. In December 2016, CytRx completed a public offering to its institutional investors of 1.9 million shares of its common stock.

  • PR Newswire3 months ago

    CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference

    LOS ANGELES, July 16, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, CytRx's President and Chief Operating Officer, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19 at 12:00 noon Eastern Daylight Time at Convene-Midtown West in New York, NY. Conference attendees consist of portfolio managers, hedge fund managers, family offices, and leading banking, trading and brokerage firms. CytRx Corporation (CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with cancer. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.  CytRx's website is www.cytrx.com.

  • PR Newswire4 months ago

    CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

    LOS ANGELES, June 28, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with triple negative breast cancer (TNBC). This is the third trial conducted by NantCell which will investigate aldoxorubicin combined with immunotherapy or high-affinity natural killer (haNK) cell therapy in certain high unmet need cancer indications.

  • PR Newswire4 months ago

    CytRx Corporation Joins Russell Microcap® Index

    LOS ANGELES, June 25, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has been added to the Russell Microcap® Index, effective upon the market opening today, Monday, June 25, 2018. "We are honored to be added to the Russell Microcap® Index," said  Eric Curtis, CytRx's President and Chief Operating Officer. The Russell indexes are broadly referenced as benchmarks by active investment strategists and institutional investors for index funds.

  • PR Newswire4 months ago

    CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology

    LOS ANGELES, June 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted data on NantCell Inc's aldoxorubicin which was published in the peer-reviewed journal Future Oncology. The paper, published on June 5, 2018, is entitled "Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma" and can be accessed online here.

  • PR Newswire4 months ago

    CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting

    LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, in Chicago. The data clearly demonstrates the lack of cardiac toxicity associated with treatment with aldoxorubicin.

  • PR Newswire5 months ago

    CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

    LOS ANGELES, June 4, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned subsidiary that will focus on advancing the Company's proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates.  CytRx has transferred to Centurion BioPharma all of the assets, liabilities and personnel associated with its laboratory operations in Freiburg, Germany. Administrative Offices are located in Los Angeles, California.

  • PR Newswire5 months ago

    CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference

    LOS ANGELES, May 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. John Caloz, Chief Financial Officer, will present at the 8th Annual LD Micro Invitational Conference on Tuesday, June 5, 2018 at 1:30 P.M. Pacific Daylight Time at the Luxe Sunset Boulevard Hotel in Bel-Air. Mr. Caloz will discuss the LADR™ platform, its broad potential in treating various tumor types, its advantages over antibody drug conjugates and an example of a LADR™ surrogate product proof of concept (aldoxorubicin).  He will also address the goal of obtaining pharmaceutical partnerships to develop the LADR™ pipeline candidates that are eligible for Investigational New Drug (IND)-enabling studies. In excess of 1,000 people are expected to attend the Invitational, to hear presentations from more than 200 leading microcap companies.

  • PR Newswire5 months ago

    CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting

    LOS ANGELES, May 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldoxorubicin will be featured in a poster presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, taking place June 1-5, 2018 in Chicago. The data were obtained from two clinical trials of aldoxorubicin, a rationally-engineered cytotoxic which employs a linker bound to albumin to deliver doxorubicin directly into the tumor.

  • PR Newswire5 months ago

    CytRx Announces Closing of $7.0 Million Registered Direct Offering

    After deducting the placement agent's fees and estimated offering expenses, the net proceeds to CytRx were approximately $6.5 million. CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers. The shares of common stock were sold pursuant to a "shelf" registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on April 21, 2017.

  • PR Newswire5 months ago

    CytRx Announces $7.0 Million Registered Direct Offering

    LOS ANGELES, May 11, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 5,600,000 shares of its common stock, at a purchase price of $1.25 per share, resulting in gross proceeds of $7.0 million. The offering is expected to close on or about May 15, 2018, subject to customary closing conditions. After deducting the placement agent's fees and estimated offering expenses, the net proceeds to CytRx are expected to be approximately $6.5 million. CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers.

  • Associated Press5 months ago

    CytRx: 1Q Earnings Snapshot

    On a per-share basis, the Los Angeles-based company said it had a loss of 15 cents. The company's shares closed at $1.89. A year ago, they were trading at $2.95. _____ This story was generated by Automated ...

  • PR Newswire5 months ago

    CytRx Reports First Quarter 2018 Financial Results

    LOS ANGELES , May 8, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ...

  • PR Newswire5 months ago

    CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018

    New President and Chief Operating Officer Mr. Eric Curtis will be Representing CytRx Corporation LOS ANGELES , May 7, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research ...

  • PR Newswire6 months ago

    CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer

    LOS ANGELES, May 3, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive management team, as President and Chief Operating Officer, effective today. Mr. Curtis brings 25 years of life science leadership experience to CytRx, with a proven track record in oncology and orphan diseases, including the development and commercialization of several approved and marketed cancer drugs such as Votrient®, Doxil®, Velcade®, Benlysta® and Tykerb®.  Most recently, he has provided strategic consultancy services to a variety of healthcare-focused companies, including CytRx.  Mr. Curtis' appointment strengthens the executive leadership team and adds significant development and operational expertise.